Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
It is potentially dangerous, which is why understanding your vial concentration is not optional
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), completed in 2023 with over 17,600 participants, demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity but without diabetes
Not managing the conversation effectively may now prove to have been a strategic oversight given the reports of plateauing efficacy, which has payers and healthcare systems questioning the long-term cost-effectiveness of GLP-1s for either weight loss or type 2 diabetes, and tightening access
Presented for research literature review only Basaki M et al
Weight Loss Program "After having my baby, I struggled to lose the extra weight and feel like myself again
100% Online & Private Convenience made for you
